Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT07083960RecruitingPhase 1
Study of OM336 for low blood cell counts caused by immune system
This trial tests a new drug called OM336 for people whose immune system is attacking their own blood cells, causing low counts. It is for those who have already tried at least one treatment that did not work well or stopped working.
Canberra, Australian Capital TerritoryAges 18–75 - NCT05371808Recruiting
Early vs delayed treatment for high-risk CLL: cost study
This study compares early treatment versus delaying treatment in newly diagnosed people with high-risk CLL/SLL who feel well. It mainly looks at the overall “costs and value” of each approach and asks patients to complete short health and quality-of-life questionnaires.
Vancouver, British ColumbiaAges 18 years+ - NCT04012905RecruitingPhase 3
Compare two steroid taper schedules for giant cell arteritis
This Phase 3 study compares how two standard steroid dose-reduction (tapering) schedules work for people with giant cell arteritis. It aims to see which taper approach controls the disease while reducing problems from long-term steroid use.
CaenAges 50 years+ - NCT04014374Recruiting
Safety study for stem cell transplant after mogamulizumab
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
Milwaukee, WisconsinAges 18 years+ - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT04025450RecruitingPhase 1/Phase 2
Tested stronger combo for high-risk myeloma patients
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Suzhou, JiangsuAges 18–80 - NCT04028531Recruiting
Understanding chronic lymphocytic leukemia in clinic patients
This study aims to learn more about chronic lymphocytic leukemia (CLL) and closely related conditions. It may help researchers better understand who gets CLL and how it behaves over time, which can improve future care.
Boston, MassachusettsAges 18 years+ - NCT04039763Recruiting
Glucose monitoring for young adults at risk of DKA
This study tests a real-time glucose monitor (RT-CGM) to help young adults with insulin-treated diabetes recognize dangerously high or fast-changing blood sugars. It may help lower the risk of diabetic ketoacidosis (DKA), a serious complication that can lead to urgent care or hospital stays.
LondonAges 18–25 - NCT04039945Recruiting
Early checkup and care program for type 1 diabetes
This study looks at early diagnosis and support for people with type 1 diabetes. You may be invited to participate if a parent or guardian agrees to enroll your child.
MunichAges 2–10 - NCT04043494RecruitingPhase 3
Study of new treatment plans for childhood lymphoblastic lymphoma
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
GrazAges Up to 18 years - NCT04045587Recruiting
Registry for severe asthma in adults in Canada
This is a research registry that collects health information from adults with severe asthma to better understand how the condition behaves and how treatments are used. You may be able to take part if your asthma is considered severe and is not well controlled.
Edmonton, AlbertaAges 18 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT04052022Recruiting
Study of TB flare-ups in people without HIV
This study looks at why some people with tuberculosis (TB) get worse or develop new inflammation after they initially start improving on treatment—called a “paradoxical reaction.” It collects blood and tissue samples to better understand these flare-ups and guide future care.
Bethesda, MarylandAges 18–99 - NCT04053439Recruiting
Testing blood-clone risk to prevent chemotherapy complications
This study looks at a specific genetic/production change in blood-forming cells (“clonal hematopoiesis”) to understand who is more likely to have complications from lymphoma chemotherapy. It may help doctors predict risk and possibly reduce harmful side effects.
Toronto, OntarioAges 60 years+ - NCT04061512RecruitingPhase 2/Phase 3
Rituximab plus ibrutinib versus standard steroids plus rituximab
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
BathAges 18 years+ - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Duarte, CaliforniaAges 4 weeks+ - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04084067RecruitingPhase 1
ICG dye helps surgeons remove tumors
This early-phase study tests whether a special dye can help doctors see a tumor more clearly during surgery in children and young people. If you have a solid tumor or certain lymphomas that need removal, the dye may help guide the surgeon to the right tissue.
Memphis, TennesseeAges Any age - NCT04083495RecruitingPhase 2
CAR T treatment for relapsed CD30-positive T-cell lymphoma
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Chapel Hill, North CarolinaAges 18–99 - NCT04094311RecruitingPhase 3
Testing a modified cell therapy when product quality is off-spec
This study looks at using tisagenlecleucel, a cell therapy, when the final product does not meet routine “commercial release” quality standards. It focuses on whether it can still be given safely and effectively to people with serious or life-threatening illness.
Hamilton, OntarioAges birth–100 years - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT04095156Recruiting
Study of immune B cells in membranous nephropathy
This study looks at immune “B cells” in people with membranous nephropathy (a kidney disease). It includes people who have received or are being considered for B-cell–depleting treatment, aiming to better understand what drives the disease and how it may respond.
Ranica, BGAges 18 years+ - NCT04096794Recruiting
Smartphone-based research study for people with type 1 diabetes
This study is a multi-site project designed for people who have type 1 diabetes and can use a smartphone app (WeChat or a similar app). It aims to collect research information in a way that’s easier to follow day to day, which may help improve future care for type 1 diabetes.
Changsha, HunanAges Any age - NCT04097067Recruiting
Radiation therapy for slow-growing stomach lymphoma
This study tests whether a specific course of focused radiation (20 Gy) can control indolent (slow-growing) lymphoma in the stomach or upper small intestine. It may help shrink or stabilize tumors and lymph node involvement while limiting side effects.
Münster, North Rhine-WestphaliaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.